NB-4746
Asset
Inhibits SARM1.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- NAD+ metabolism
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2ALS
Phase 1, nurabio.com, 7 Oct 2026
Amyotrophic lateral sclerosis
Phase 1, Recruiting, NCT07369076, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.